Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Fig. 3

KLF4 represses the EGFR signaling pathway. a Western blot analysis of KLF4, tEGFR, pEGFR (Y1068), tAKT, pAKT (S473), tERK1/2, and pERK1/2 (Y202/Y204) protein levels 3 days after AdGFP or AdKLF4 infection of MDA-MB-231 cells. b Graph depicting western blot quantification. All protein levels were normalized to total protein in the lane to control for loading, and phosphorylated proteins were normalized to their respective unphosphorylated proteins. AdKLF4 lanes were then expressed relative to AdGFP and are graphed with the horizontal bars indicating the median of the values of three replicate blots. Each dot represents the mean value from a different experiment, *p < 0.05. c, d Similar to a and b, but with lysates from infected MDA-MB-468 cells. e Western blot analysis of the same proteins in a, collected 3 days after transfection of MCF10A cells with siNS or siKLF4. f Quantitation and analysis of protein levels were completed as described in b. All western blots were completed in three independent experiments, each in triplicate, *p < 0.05

Back to article page